Commit-Kzn Team
University of KwaZulu-Natal
5 Papers
Commit-Kzn Team is an academic researcher from University of KwaZulu-Natal. The author has contributed to research in topics: Neutralization & Virus. The author has an hindex of 3, co-authored 5 publications. Previous affiliations of Commit-Kzn Team include Centre for the AIDS Programme of Research in South Africa.
Chat about Author
Papers
Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma
Sandile Cele,Inbal Gazy,Inbal Gazy,Laurelle Jackson,Shi-Hsia Hwa,Houriiyah Tegally,Gila Lustig,Jennifer Giandhari,Sureshnee Pillay,Eduan Wilkinson,Yeshnee Naidoo,Farina Karim,Yashica Ganga,Khadija Khan,Mallory Bernstein,Alejandro B. Balazs,Bernadett I Gosnell,Willem A. Hanekom,Mahomed-Yunus S. Moosa,Ngs-Sa,Commit-Kzn Team,Commit-Kzn Team,Richard J Lessells,Richard J Lessells,Tulio de Oliveira,Alex Sigal,Alex Sigal +26 more
TL;DR: In this article, a live virus neutralization assay (LVNA) was used to compare neutralization of a first wave virus (B.1.351) with mutations in the spike receptor-binding domain (RBD) and N-terminal domain (NTD).
Immunogenicity of SARS-CoV-2 infection and Ad26.CoV2.S vaccination in people living with HIV
Khadija Khan,Gila Lustig,Mallory Bernstein,Derseree Archary,Derseree Archary,Sandile Cele,Farina Karim,Muneerah Smith,Yashica Ganga,Zesuliwe Jule,Kajal Reedoy,Yoliswa Miya,Ntombifuthi Mthabela,Commit-Kzn Team,Richard J Lessells,Richard J Lessells,Tulio de Oliveira,Bernadett I Gosnell,Salim S. Abdool Karim,Nigel Garrett,Nigel Garrett,Willem A. Hanekom,Linda-Gail Bekker,Glenda Gray,Jonathan M. Blackburn,Mahomed-Yunus S. Moosa,Alex Sigal +26 more
TL;DR: In this article, the ability of the Johnson and Johnson Ad26.CoV2.S vaccine to elicit neutralizing antibodies to the Delta variant in people living with HIV relative to HIV-uninfected individuals was assessed.
HIV infection alters SARS-CoV-2 responsive immune parameters but not clinical outcomes in COVID-19 disease
Farina Karim,Inbal Gazy,Sandile Cele,Yenzekile Zungu,Robert Krause,Mallory Bernstein,Yashica Ganga,Hylton Errol Rodel,Ntombifuthi Mthabela,Matilda Mazibuko,Khadija Khan,Daniel M. Muema,Dirhona Ramjit,Gila Lustig,Thumbi Ndung'u,Willem A. Hanekom,Bernadett I Gosnell,Commit-Kzn Team,Emily B. Wong,Tulio de Oliveira,Mahomed-Yunus S. Moosa,Alasdair Leslie,Henrik N. Kløverpris,Henrik N. Kløverpris,Alex Sigal,Alex Sigal +25 more
TL;DR: The impact of HIV on the immune response to SARS-CoV-2 was investigated using longitudinal samples from 124 participants from KwaZulu-Natal, South Africa, an area of extremely high HIV prevalence and likely reflects the heterogeneity of an effective COVID-19 immune response.
SARS-CoV-2 cell-to-cell spread occurs rapidly and is insensitive to antibody neutralization
Laurelle Jackson,Hylton Errol Rodel,Shi-Hsia Hwa,Sandile Cele,Yashica Ganga,Houriiyah Tegally,Mallory Bernstein,Jennifer Giandhari,Commit-Kzn Team,Bernadett I Gosnell,Khadija Khan,Willem A. Hanekom,Farina Karim,Tulio de Oliveira,Tulio de Oliveira,Tulio de Oliveira,Mahomed-Yunus S. Moosa,Alex Sigal,Alex Sigal +18 more
TL;DR: In this paper, the authors visualized infection using time-lapse microscopy of a human lung cell line and used live virus neutralization to determine the sensitivity of SARS-CoV-2 cell-to-cell spread to neutralizing antibodies.
Similar antibody responses against SARS-CoV-2 in HIV uninfected and infected individuals on antiretroviral therapy during the first South African infection wave.
Jumari Snyman,Shi-Hsia Hwa,Robert Krause,Daniel M. Muema,Tarylee Reddy,Yashica Ganga,Farina Karim,Alasdair Leslie,Alex Sigal,Alex Sigal,Thumbi Ndung'u,Commit-Kzn Team +11 more
TL;DR: In this article, the authors longitudinally followed SARS-CoV-2 infected individuals in Durban, KwaZulu-Natal, South Africa and characterized SARS receptor binding domain-specific IgM, IgG and IgA antibodies weekly for a month, and then at 3 months post diagnosis.